Does the Trans-Pacific Partnership and the proposed India-EU trade deal extend protection of Intellectual Property Rights, delaying generic competition for life-saving drugs, and keeping their prices high? While these, and other possible implications for the Indian consumers and pharma companies become clearer over time, India must robustly engage with the debate on trade deals and public interest
Global opinion is sharply divided about the ramifications of the recently concluded Trans-Pacific Partnership (TPP). A part of U.S. President Barack Obama’s ‘pivot to Asia’, the TPP includes the United States and 11 other Pacific Rim countries (Brunei, Chile, Singapore, New Zealand, Australia, Canada, Japan, Malaysia, Mexico, Peru, and Vietnam).